guest ::
| Home > Articles > Published articles > COVID-19 severity and vaccine breakthrough infections in idiopathic inflammatory myopathies, other systemic autoimmune and inflammatory diseases, and healthy controls : |
| Home > Articles > Published articles > COVID-19 severity and vaccine breakthrough infections in idiopathic inflammatory myopathies, other systemic autoimmune and inflammatory diseases, and healthy controls : |
(Universidade Potiguar (Brasil)) (Sanjay Gandhi Postgraduate Institute of Medical Sciences) (Universidade de Sao Paulo) (University of Melbourne) (Maulana Azad Medical College) (Universidade de Sao Paulo) (Northern Care Alliance NHS Foundation Trust) (Byramjee Jeejeebhoy Government Medical College) (Mahatma Gandhi Mission Medical College) (Istanbul University) (University of Illinois College of Medicine. Center for Outcomes Research, Department of Internal Medicine) (Pomeranian Medical University in Szczecin) (Mayo Clinic) (Cairo University) (Fauji Foundation Hospital) (University Hospital "Lozenetz") (General Hospital, National Medical Center, La Raza") (Örebro University) (Hospital Universitari Vall d'Hebron) (King's College Hospital NHS Foundation Trust) (University of Leeds) (University of Illinois College of Medicine) (Università degli studi di Pavia) (Centro Médico Nacional La Raza) (Hotel-Dieu de France Hospital) (Universitätsklinikum Erlangen) (Nippon Medical School Graduate School of Medicine) (Southport and Ormskirk Hospitals NHS Trust) (University Hospital Zurich (Suïssa)) (Eskişehir Osmangazi University) (St Luke's Medical Center-Global City) (Universitas Indonesia) (Instituto Mexicano del Seguro Social Delegación Yucatán) (Instituto Nacional de Enfermedades Respiratorias) (Hospital General de Occidente and University of Guadalajara) (University College London. Centre for Adolescent Rheumatology Versus Arthritis) (North Bristol NHS Trust) (Salford Royal Hospital) (Sanjay Gandhi Postgraduate Institute of Medical Sciences) (University of Pittsburgh School of Medicine) (City Hospital, Sandwell and West Birmingham Hospitals NHS Trust)| Date: | 2022 |
| Abstract: | We aimed to compare the spectrum and severity of COVID-19 and vaccine breakthrough infections (BIs) among patients with IIMs, other systemic autoimmune and inflammatory diseases (SAIDs), and healthy controls (HCs). This is a cross-sectional study with data from the COVAD study, a self-reported online global survey that collected demographics, COVID-19 history, and vaccination details from April to September 2021. Adult patients with at least one COVID-19 vaccine dose were included. BIs were defined as infections occurring > 2 weeks after any dose of vaccine. Characteristics associated with BI were analyzed with a multivariate regression analysis. Among 10,900 respondents [42 (30-55) years, 74%-females, 45%-Caucasians] HCs were (47%), SAIDs (42%) and IIMs (11%). Patients with IIMs reported fewer COVID-19 cases before vaccination (6. 2%-IIM vs 10. 5%-SAIDs vs 14. 6%-HC; OR = 0. 6, 95% CI 0. 4-0. 8, and OR = 0. 3, 95% CI 0. 2-0. 5, respectively). BIs were uncommon (1. 4%-IIM; 1. 9%-SAIDs; 3. 2%-HC) and occurred in 17 IIM patients, 13 of whom were on immunosuppressants, and 3(18%) required hospitalization. All-cause hospitalization was higher in patients with IIM compared to HCs [23 (30%) vs 59 (8%), OR = 2. 5, 95% CI 1. 2-5. 1 before vaccination, and 3 (18%) vs 9 (5%), OR = 2. 6, 95% CI 1. 3-5. 3 in BI]. In a multivariate regression analysis, age 30-60 years was associated with a lower odds of BI (OR = 0. 7, 95% CI 0. 5-1. 0), while the use of immunosuppressants had a higher odds of BI (OR = 1. 6, 95% CI 1. 1-2. 7). Patients with IIMs reported fewer COVID-19 cases than HCs and other SAIDs, but had higher odds of all-cause hospitalization from COVID-19 than HCs. BIs were associated with the use of immunosuppressants and were uncommon in IIMs. The online version contains supplementary material available at 10. 1007/s00296-022-05229-. |
| Rights: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.  |
| Language: | Anglès |
| Document: | Article ; recerca ; Versió publicada |
| Subject: | Autoimmune diseases ; Breakthrough infection ; COVID-19 ; Idiopathic inflammatory myopathies ; SARS-CoV-2 vaccination |
| Published in: | Rheumatology International, october 2022, p. 1-12, ISSN 1437-160X |
